u/Feel-Wonderful

For decades, the male body was treated as the default in biomedical research.

As Dr. Jennifer Garrison has highlighted, women were often excluded from clinical trials because hormonal cycles were considered "too complicated," and because of concerns that experimental treatments could affect a pregnancy.

As a result, many medications, disease models, and treatment guidelines were developed using predominantly male participants. Female biology remained underrepresented across biomedical research, with female animals often excluded from laboratory studies until sex became a required biological variable in federally funded preclinical research in 2016.

Decades of underrepresentation left major gaps in our understanding of female biology. One of the most significant consequences is how much we still have to learn about ovarian biology.

Far beyond reproduction, the ovaries help regulate hormones that influence the brain, bones, muscles, metabolism, cardiovascular health, and immune function. Their health has profound implications for women's healthspan and longevity, yet for decades, one of the organs most central to healthy aging received remarkably little scientific attention.

Better science starts with studying everyone.

Learn more at getwonderfeel.com/learn.

Wonderfeel ranked #1 in Biotech on the 2026 Inc. 5000, placing #65 overall and #12 in California among America's fastest-growing private companies.

Wonderfeel is built on a commitment to pushing the boundaries of cellular energetics and expanding what's possible for human healthspan.

Over the years, that commitment has driven scientific research, product development, and, more recently, new advances in cellular diagnostics. Alongside our work in nutraceuticals, we're expanding our research into critical areas including gut barrier function and cognitive performance, bringing us closer to the next generation of healthspan innovations.

This recognition reflects the work of an incredible team of doctors, scientists, entrepreneurs, and creators who continue to ask bigger questions and pursue better answers.

To everyone who's made Wonderfeel part of your daily routine and supported our mission, thank you. Your belief in what we're building has made this milestone possible.

Here's to the next breakthrough.

#Inc5000 #Biotech #Healthspan

One variable that might explain inconsistent results with NAD supplementation: CD 38.

CD38 is a major NAD-consuming enzyme that converts NAD into ADP-ribose and related metabolites. Its expression increases with age and inflammation, which accelerates NAD turnover, meaning NAD levels aren't just a function of how much precursor you take, but also how quickly it's being degraded.

That creates a scenario where increasing NMN or NR alone may have diminishing returns if CD38 activity remains elevated. 

This came up in a recent podcast where Wonderfeel's cofounder and CEO, Baran Dilaver, joined Dave Asprey. Dave pointed out that his main concern with NMN alone is CD38—describing it as an inflammatory enzyme that essentially consumes NAD as fast as you're making it. He also mentioned that pairing NAD precursors with compounds like hydroxytyrosol may be worth exploring, as it could help counterbalance that breakdown.

A more complete approach would consider not just supporting NAD synthesis, but also reducing NAD consumption and managing the inflammation that drives CD38 activity in the first place. 

Curious if anyone here has tried approaching NAD from the “reduce breakdown” side instead of just increasing precursors.